Compare FCBC & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FCBC | RGNX |
|---|---|---|
| Founded | 1874 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 928.3M | 793.5M |
| IPO Year | 1996 | 2015 |
| Metric | FCBC | RGNX |
|---|---|---|
| Price | $47.79 | $6.87 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $23.58 |
| AVG Volume (30 Days) | 74.0K | ★ 1.4M |
| Earning Date | 10-27-2026 | 11-05-2026 |
| Dividend Yield | ★ 4.84% | N/A |
| EPS Growth | N/A | ★ 18.08 |
| EPS | ★ 1.82 | N/A |
| Revenue | N/A | ★ $10,393,000.00 |
| Revenue This Year | $17.48 | N/A |
| Revenue Next Year | N/A | $22.42 |
| P/E Ratio | $26.35 | ★ N/A |
| Revenue Growth | N/A | ★ 126.48 |
| 52 Week Low | $31.21 | $5.46 |
| 52 Week High | $50.17 | $16.19 |
| Indicator | FCBC | RGNX |
|---|---|---|
| Relative Strength Index (RSI) | 53.73 | 34.77 |
| Support Level | $47.54 | $5.67 |
| Resistance Level | $49.57 | $7.32 |
| Average True Range (ATR) | 0.98 | 0.46 |
| MACD | 0.08 | 0.04 |
| Stochastic Oscillator | 59.01 | 5.96 |
First Community Bankshares Inc is a financial holding company that provides commercial banking products and services. The company is engaged in providing demand deposit accounts, savings, and money market accounts, certificates of deposits; commercial, consumer, and real estate mortgage loans, and lines of credit; various credit card, debit card, and automated teller machine card services; corporate and personal trust services; investment management services and life, health, and property and casualty insurance products. The company's revenue is mainly derived from interest, fees, and commissions.
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.